Total amount: € 0,00
HOW TO ORDER
GAZZETTA MEDICA ITALIANA ARCHIVIO PER LE SCIENZE MEDICHE
A Journal on Internal Medicine and Pharmacology
Indexed/Abstracted in: BIOSIS Previews, EMBASE, Scopus, Emerging Sources Citation Index
Gazzetta Medica Italiana Archivio per le Scienze Mediche 2002 June;161(3):129-34
Effects of hormone replacement therapy on uterine leiomyomas in postmenopausal woman
Lo Dico G., Alongi G., Lucido A. M., Biondo Dagnino S., Domianello D.
Istituto di Ginecologia e Ostetricia, Cattedra di Ginecologia Endocrinologica, Università degli Studi di Palermo, Palermo
Background. To evaluate the bleeding pattern and the effects on the uterine size in post-menopausal women with asymptomatic uterine leiomyomas treated with hormone replacement therapy.
Methods. In this prospective comparative study 150 postmenopausal women were enrolled into two groups. I Group: 80 women with asymptomatic leiomyomas. II Group: 70 women with uterine fibroids as control. One hundred and twenty patients were treated with continuous sequential therapy with 17β E2 0.05 mg/24 hrs transdermal and norethisterone A. 0.25 mg/24 hrs for 14 days (26 cases), dydrogesterone 10 mg/day for 12 days (78 cases), nomegestrol 5 mg/day for 12 days (24 cases); 31 patients were treated with a continuous combinated treatment with estradiol 2 mg/day for 28 days and norethisterone A 1 mg/day for 28 days. The therapy has been given for 2-7 years. We have evaluated the beginning, duration time and intensity of bleeding, and volume modification of uterine leiomyoma.
Results. The patients treated with continuous sequential therapy showed a significant regularity of appearance, duration and intensity of bleeding without significant difference between the two groups and without any relation to the progestinic given. The patients treated with a continuous combinated treatment presented amenorrhea in 80% and spotting in 20% of cases. The transvaginal sonography showed no significant changes in the leiomyomas volume.
Conclusions. The results show no clinical indications to contraindicate HRT in the post-menopausal woman with leiomyomas.